Kewaunee Scientific (KEQU) AI Stock Analysis

• Market Cap: $166.16M
• Dividend Yield: N/A
• Average Volume (3M): 13.07K
• Price to Earnings (P/E): 15.3
• Beta (1Y): 0.74
• Revenue Growth: 18.02%
• EPS Growth: -38.98%
• Country: US
• Employees: 1,006
• Sector: Consumer Cyclical
• Sector Strength: 61
• Industry: Furnishings, Fixtures & Appliances
• EPS (TTM): 1.95
• Shares Outstanding: 2,844,290
• 10 Day Avg. Volume: 27,863
• 30 Day Avg. Volume: 13,066
• PEG Ratio: -0.41
• Price to Book (P/B): 2.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.92
• Enterprise Value/Market Cap: 1.19
• Enterprise Value/Revenue: 0.23
• Enterprise Value/Gross Profit: 2.88
• Enterprise Value/Ebitda: 2.82
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: $64.00 ▲(9.55%Upside)

The stock is supported by strong financial performance, particularly in revenue growth and operational efficiency. Reasonable valuation adds to its attractiveness. Technical indicators signal bullish momentum but caution against potential corrections. The absence of earnings call and corporate events data leads to a moderate overall score.

Kewaunee Scientific Business Overview & Revenue Model

Company Description

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates through two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, its subidiaries, and a national distributor. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.

How the Company Makes Money

Kewaunee Scientific makes money primarily through the sale of its laboratory furniture products and related services. The company's revenue streams include direct sales to end-users, which encompass educational institutions, healthcare facilities, and industrial laboratories. Additionally, Kewaunee partners with distributors and dealers to reach a broader market. The company also generates income through installation and maintenance services, ensuring the proper setup and long-term functionality of its products. Key factors contributing to its earnings include its reputation for high-quality products, a strong presence in both domestic and international markets, and its ability to customize solutions to meet specific client needs.

Kewaunee Scientific Financial Statement Overview

Summary

Kewaunee Scientific demonstrates strong revenue growth and improved gross profit margins, indicating enhanced operational efficiency. However, fluctuating net profit margins and increasing leverage present potential risks. Cash flow has improved, though past volatility suggests the need for ongoing management.

Income Statement

Kewaunee Scientific has shown strong revenue growth, increasing from $147.5M in 2020 to $240.5M in 2025, highlighting a robust growth trajectory. Gross profit margins have improved significantly over the years, with a notable increase in EBIT and EBITDA margins, reflecting enhanced operational efficiency. However, net profit margin has fluctuated, indicating some volatility in bottom-line profitability despite the upward trend.

Balance Sheet

The company's debt-to-equity ratio has increased, indicating higher leverage, but remains manageable within industry norms. Stockholders' equity has grown, supporting a stable equity ratio. Return on equity has improved significantly, driven by rising net income, which suggests strengthening shareholder value. However, the rising debt levels could be a potential risk if not managed carefully.

Cash Flow

Kewaunee Scientific has experienced volatility in cash flow from operations, with recent improvements in free cash flow growth. The operating cash flow to net income ratio indicates healthy cash generation relative to earnings. The free cash flow conversion is positive, but past years showed negative free cash flow, suggesting potential liquidity pressures during those periods. Continuous improvement in cash flow management is essential.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	240.47M	203.75M	219.49M	168.87M	147.47M
Gross Profit	68.86M	52.05M	35.59M	24.22M	23.99M
EBITDA	22.76M	18.04M	8.16M	916.00K	459.00K
Net Income	11.40M	18.75M	1.36M	-6.00M	-3.61M
Balance Sheet
Total Assets	194.65M	134.77M	118.90M	118.77M	89.38M
Cash, Cash Equivalents and Short-Term Investments	14.94M	23.27M	8.08M	4.43M	5.21M
Total Debt	50.16M	11.00M	12.92M	9.44M	16.15M
Total Liabilities	128.41M	78.56M	80.41M	82.59M	47.90M
Stockholders Equity	64.46M	54.76M	37.41M	35.69M	41.24M
Cash Flow
Free Cash Flow	12.62M	15.19M	-7.94M	-9.79M	-1.49M
Operating Cash Flow	14.78M	19.56M	-3.79M	-7.88M	912.00K
Investing Cash Flow	-30.90M	-4.37M	-4.15M	-1.91M	-2.40M
Financing Cash Flow	7.41M	-3.01M	14.93M	11.03M	1.98M

Kewaunee Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 58.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Positive. The current price of 58.42 is above the 20-day moving average (MA) of 45.94, above the 50-day MA of 39.98, and above the 200-day MA of 44.34, indicating a bullish trend. The MACD of 5.65 indicates Negative momentum. The RSI at 74.31 is Negative, neither overbought nor oversold. The STOCH value of 91.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KEQU.

Kewaunee Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETD	71 Outperform	$748.91M	13.06	12.09%	5.18%	-6.32%	-18.35%
KEQU	70 Outperform	$166.16M	15.25	19.13%	―	18.02%	-38.98%
LZB	68 Neutral	$1.60B	16.60	9.84%	2.22%	3.04%	-16.49%
Sector *	62 Neutral	C$5.18B	11.26	18.64%	3.62%	3.35%	6.70%
BSET	51 Neutral	$149.62M	―	-3.83%	4.97%	-11.78%	-13.89%
HOFT	50 Neutral	$119.59M	―	-5.55%	7.99%	-3.89%	-391.05%
SNBR	43 Neutral	$176.52M	―	9.10%	―	-12.36%	37.69%

Kewaunee Scientific Corporate Events

Kewaunee Scientific to Release Q4 Results June 25

On June 11, 2025, Kewaunee Scientific Corporation announced its plan to release the financial results for its fourth quarter and fiscal year ending April 30, 2025, on June 25, 2025, after market close. The announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, especially following its acquisition of Nu Aire, which is expected to bolster its market position in laboratory and healthcare furniture products.